ClinicalTrials.gg

Glioblastoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,135 studies for Glioblastoma across more than 10 countries. 465 are recruiting or about to start. 1,606 of them are mainly about Glioblastoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,288 studies for Glioblastoma. How that becomes 2,135 here

This page counts the studies the registry files under Glioblastoma, and those it files under no condition that list Glioblastomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,288Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −29List Glioblastoma as a condition, but the registry did not file them under itMost often written as “Glioblastoma Multiforme of Brain” (4), “Recurrent Childhood Glioblastoma” (3), and “Adult Brain Glioblastoma” (2). The registry filed them under other conditions only, most often Brain Neoplasms (10) and Glioma (8).
  3. −124Match it another way74 name it in the title, 4 in a keyword, and 46 by a synonym or other text the search reads.
  4. 2,135The count on this page59 of them list Glioblastoma in their own words; the registry filed them under no condition.

Status

Completed
962
Recruiting
340
Terminated
258
Active, not recruiting
176
Status unknown
155
Not yet recruiting
110

Phase

Phase 2
912
Phase 1
833
Phase 3
115
Early Phase 1
95
Phase 4
8

Where

United States
1,302
France
150
China
142
Germany
133
Canada
118
Spain
95

Who develops what

Add Glioblastoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 40 programs from 34 companies, 29 with this as their studies’ main aim; 2 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Beijing Biotech, Jecho Biopharmaceuticals and AstraZeneca here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TemozolomideRecent, repeated
Evidence
  • NCT07811297 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Temozolomide (TMZ)” · registered Aug 2026
  • NCT07762716 · BreakBio Corp · Phase 2 · live · background · “Temozolomide (TMZ)” · registered Aug 2026
  • NCT07349693 · Everfront Biotech Co., Ltd. · Phase 3 · live · background · “Temozolomide (for relapsed malignant glioma)” · registered Jan 2026
  • NCT07326566 · Black Diamond Therapeutics, Inc. · Phase 2 · live · comparator · “temozolomide (TMZ)” · registered Jan 2026
  • NCT07365280 · zsky biotech inc · Phase 2 · live · background · “Temozolomide (TMZ)” · registered Jan 2026
Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized1313 studies
BevacizumabRecent, repeated
Evidence
  • NCT07297212 · BioNTech SE · Phase 2 · live · comparator · “Bevacizumab” · registered Dec 2025
  • NCT06496971 · NaviFUS Corporation · Phase 3 · live · background · “Bevacizumab” · registered Jul 2024
  • NCT06061809 · ImmunityBio, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Sep 2023
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
  • NCT05191784 · Genexine, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Nov 2021
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others44 studies
LomustineRecent, repeated
Evidence
  • NCT07811297 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “CCNU” · registered Aug 2026
  • NCT06336291 · Philogen S.p.A. · Phase 2 · live · background · “Lomustine” · registered Mar 2024
  • NCT05902169 · carthera · Phase 3 · live · comparator · “Lomustine” · registered Jun 2023
  • NCT04762069 · CNS Pharmaceuticals, Inc. · Phase 2 · live · comparator · “Lomustine” · registered Nov 2020
  • NCT04573192 · Philogen S.p.A. · Phase 2 · live · background · “Lomustine” · registered Sep 2020
Philogen S.p.A.22% of its industry studiesUS: off-patent, 1 generic marketed33 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07762716 · BreakBio Corp · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
  • NCT04479241 · Istari Oncology, Inc. · Phase 2 · background · “pembrolizumab” · registered Jul 2020
  • NCT04121455 · TME Pharma AG · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2019
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)22 studies
IpilimumabRecent, repeated
Evidence
  • NCT07762716 · BreakBio Corp · Phase 2 · live · background · “Ipilimumab 2.5 mg” · registered Aug 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Ipilimumab” · registered Aug 2023
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)22 studies

20 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Iodine I 131 IPA☆ Track1 live phase-3 study: NCT07100730Telix Pharmaceuticals Limited
Cerebraca wafer☆ Track1 live phase-3 study: NCT07349693Everfront Biotech Co., Ltd.

The 2 in phase 3 with the nearest primary completion, of 40 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.Non-muscle Myosin IIA/IIB Inhibitor MT-125 · Myosin Therapeutics Inc. · Phase 2 main aimNCT07604285 A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma — primary endpoint: Dose Limiting Toxicity Measurement · 36 enrolled
  • 31 Mar 2027 est.PRMT5 Inhibitor TNG456 · Tango Therapeutics, Inc. · Phase 2 named, not the main aimNCT06810544 Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss — primary endpoint: Phase 1 Maximum Tolerated Dose · 191 enrolled
  • 14 Apr 2027 est.Cyclophosphamide, fludarabine, Autologous dual-target CAR-T cells selected from the predefined target library. · Beijing Biotech · Phase 2 registry mapping onlyNCT07523529 Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors — primary endpoint: Dose-limiting toxicities (DLTs) · 72 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Glioblastoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 30 open · Immune checkpoint inhibitors 22 open · Tyrosine kinase inhibitors (TKIs) 18 open · Angiogenesis inhibitors 9 open · Antimetabolites 7 open

Coming up

187studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger. 27 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 14 (4%) take healthy volunteers.

Recruiting studies that take each age, of 340
AgeWomenMen
1022 (6%)22 (6%)
18327 (96%)327 (96%)
30328 (96%)328 (96%)
40327 (96%)327 (96%)
50327 (96%)327 (96%)
65328 (96%)328 (96%)
75296 (87%)296 (87%)
85260 (76%)260 (76%)

Across all 2,135 studies, recruiting or not: 17% stop at 75 or younger and 6% at 65; 9% take children; 0% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Glioblastoma studies take

Of 321 phase 1 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 144 mo29–73 · 321 studies42 mo27–64 · 82 studies45 mo31–76 · 239 studies
Phase 1/266 mo45–102 · 137 studies55 mo39–75 · 52 studies75 mo50–105 · 85 studies
Phase 255 mo40–87 · 249 studies44 mo35–58 · 51 studies59 mo41–88 · 198 studies
Phase 348 mo44–87 · 44 studies——
Interventional, no phase54 mo36–88 · 151 studies—54 mo37–97 · 133 studies
Observational52 mo33–96 · 100 studies—55 mo33–96 · 85 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 2,135. Browse all 2,135 → or search them.